ATE502647T1 - Zubereitungen enthaltend sincalide - Google Patents
Zubereitungen enthaltend sincalideInfo
- Publication number
- ATE502647T1 ATE502647T1 AT03818433T AT03818433T ATE502647T1 AT E502647 T1 ATE502647 T1 AT E502647T1 AT 03818433 T AT03818433 T AT 03818433T AT 03818433 T AT03818433 T AT 03818433T AT E502647 T1 ATE502647 T1 AT E502647T1
- Authority
- AT
- Austria
- Prior art keywords
- sincalide
- preparations containing
- methods
- formulations
- sincalide formulations
- Prior art date
Links
- 108010087230 Sincalide Proteins 0.000 title abstract 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title abstract 5
- 229960002959 sincalide Drugs 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/222,540 US6803046B2 (en) | 2002-08-16 | 2002-08-16 | Sincalide formulations |
| PCT/IB2003/006513 WO2005027954A2 (en) | 2002-08-16 | 2003-08-15 | Sincalide formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE502647T1 true ATE502647T1 (de) | 2011-04-15 |
Family
ID=31714996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03818433T ATE502647T1 (de) | 2002-08-16 | 2003-08-15 | Zubereitungen enthaltend sincalide |
Country Status (9)
| Country | Link |
|---|---|
| US (13) | US6803046B2 (de) |
| EP (1) | EP1631305B1 (de) |
| JP (1) | JP4751993B2 (de) |
| CN (1) | CN100374154C (de) |
| AT (1) | ATE502647T1 (de) |
| AU (1) | AU2003304382B2 (de) |
| CA (1) | CA2503982C (de) |
| DE (1) | DE60336509D1 (de) |
| WO (1) | WO2005027954A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007520A2 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
| US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
| US20070243264A1 (en) * | 2006-04-18 | 2007-10-18 | Aram Garabedian | Thickened Dilute Hypochlorite |
| US7923425B2 (en) * | 2006-08-21 | 2011-04-12 | Henkel Ag & Co. Kgaa | Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces |
| BRPI0718374A2 (pt) | 2006-09-29 | 2013-06-25 | Johnson & Johnson Vision Care | mÉtodos e dispositivos oftÁlmicos usados no tratamento de alergias oculares |
| US20080098614A1 (en) * | 2006-10-03 | 2008-05-01 | Wyeth | Lyophilization methods and apparatuses |
| WO2008077712A1 (en) * | 2006-12-22 | 2008-07-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| US9801818B2 (en) * | 2007-12-31 | 2017-10-31 | Samyang Biopharmaceuticals Corporation | Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug |
| EP2236520A1 (de) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilisierungszusammensetzung für immobilisierte Biomoleküle |
| CN103027890B (zh) * | 2011-09-29 | 2014-06-18 | 天津市汉康医药生物技术有限公司 | 供注射用的布洛芬药物组合物 |
| HUE032392T2 (en) | 2012-11-20 | 2017-09-28 | Fresenius Kabi Usa Llc | Kaszpofunginacetát compositions |
| PL2926805T3 (pl) | 2014-03-31 | 2016-12-30 | Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji | |
| CN104761645A (zh) * | 2015-04-30 | 2015-07-08 | 山东禹王制药有限公司 | α干扰素融合蛋白制剂及应用 |
| JP6491747B2 (ja) | 2015-09-30 | 2019-03-27 | デューク・ユニヴァーシティ | 磁気共鳴画像法用の造影剤 |
| US20180360917A1 (en) * | 2017-06-15 | 2018-12-20 | Apicore Llc | Sincalide formulations and methods of use |
| US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
| WO2019099965A1 (en) * | 2017-11-20 | 2019-05-23 | Just Biotherapeutics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| EP3863686A1 (de) * | 2018-10-12 | 2021-08-18 | Advanced Accelerator Applications International S.A. | Pharmazeutische zusammensetzung mit einem radiomarkierten gprp-antagonisten und einem tensid |
| WO2022071822A1 (en) | 2020-09-29 | 2022-04-07 | Limited Liability Company "Topcon Positioning Systems" | Maneuvering system for autonomous wheeled robot for optimally reaching starting point |
| JP2023119488A (ja) * | 2022-02-16 | 2023-08-28 | ニプロ株式会社 | スガマデクス含有の液体製剤 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723406A (en) | 1969-12-23 | 1973-03-27 | Squibb & Sons Inc | Novel peptides having cholecystokinin activity and intermediates therefor |
| US3937819A (en) * | 1974-07-22 | 1976-02-10 | E. R. Squibb & Sons, Inc. | Method of stabilizing an injectable composition of a cholecystokinin active octapeptide |
| IT1204430B (it) * | 1986-01-10 | 1989-03-01 | Alfio Bertolini | Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria |
| US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
| JPH03505334A (ja) * | 1989-04-11 | 1991-11-21 | イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド | 凍結乾燥されたペプチド製剤 |
| US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
| IN172208B (de) | 1990-04-02 | 1993-05-01 | Sint Sa | |
| TW274552B (de) * | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
| US5373613A (en) | 1992-10-23 | 1994-12-20 | Young Engineering, Inc. | Tenter frame with pinned roll transfer means |
| JPH06273415A (ja) * | 1993-03-18 | 1994-09-30 | Unitika Ltd | コレシストキニンの測定用試薬及び測定方法 |
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
| US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| US5833948A (en) | 1995-06-15 | 1998-11-10 | Bracco Research S.A. | Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant |
| DE19645250A1 (de) | 1996-11-02 | 1998-05-07 | Merck Patent Gmbh | Stabile wäßrige Formulierung von 3-(N-Butylacetamino)-propionsäureethylester |
| CH692322A5 (it) | 1997-05-26 | 2002-05-15 | Westy Ag | Formulazione iniettabile limpida di Propofol. |
| DE69928563T2 (de) * | 1998-12-09 | 2006-07-27 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| SE9901578D0 (sv) * | 1999-05-03 | 1999-05-03 | Karolinska Innovations Ab | New use of substance in PNS |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| US6579521B2 (en) * | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
-
2002
- 2002-08-16 US US10/222,540 patent/US6803046B2/en not_active Expired - Lifetime
-
2003
- 2003-08-15 CA CA2503982A patent/CA2503982C/en not_active Expired - Lifetime
- 2003-08-15 CN CNB038241374A patent/CN100374154C/zh not_active Expired - Lifetime
- 2003-08-15 WO PCT/IB2003/006513 patent/WO2005027954A2/en not_active Ceased
- 2003-08-15 JP JP2005509018A patent/JP4751993B2/ja not_active Expired - Lifetime
- 2003-08-15 EP EP03818433A patent/EP1631305B1/de not_active Expired - Lifetime
- 2003-08-15 AU AU2003304382A patent/AU2003304382B2/en not_active Expired
- 2003-08-15 DE DE60336509T patent/DE60336509D1/de not_active Expired - Lifetime
- 2003-08-15 AT AT03818433T patent/ATE502647T1/de not_active IP Right Cessation
-
2004
- 2004-08-19 US US10/921,732 patent/US20050020502A1/en not_active Abandoned
-
2009
- 2009-10-28 US US12/607,337 patent/US20100047175A1/en not_active Abandoned
-
2011
- 2011-12-02 US US13/309,848 patent/US20120128581A1/en not_active Abandoned
-
2013
- 2013-10-28 US US14/064,379 patent/US20140065071A1/en not_active Abandoned
-
2014
- 2014-10-02 US US14/504,498 patent/US20150017097A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/696,658 patent/US20150224166A1/en not_active Abandoned
-
2016
- 2016-09-30 US US15/281,489 patent/US20170014470A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,471 patent/US20170281719A1/en not_active Abandoned
- 2017-11-08 US US15/807,555 patent/US20180064781A1/en not_active Abandoned
-
2019
- 2019-10-01 US US16/589,230 patent/US20200030406A1/en not_active Abandoned
-
2020
- 2020-04-27 US US16/858,815 patent/US20200254052A1/en not_active Abandoned
- 2020-10-01 US US17/060,191 patent/US20210093689A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1631305B1 (de) | 2011-03-23 |
| JP4751993B2 (ja) | 2011-08-17 |
| US20200030406A1 (en) | 2020-01-30 |
| CA2503982A1 (en) | 2005-03-31 |
| AU2003304382B2 (en) | 2008-11-06 |
| EP1631305A2 (de) | 2006-03-08 |
| AU2003304382A1 (en) | 2005-04-28 |
| US20170014470A1 (en) | 2017-01-19 |
| US20150017097A1 (en) | 2015-01-15 |
| CN1756557A (zh) | 2006-04-05 |
| US20140065071A1 (en) | 2014-03-06 |
| CA2503982C (en) | 2011-09-27 |
| US20200254052A1 (en) | 2020-08-13 |
| US20180064781A1 (en) | 2018-03-08 |
| DE60336509D1 (de) | 2011-05-05 |
| US20100047175A1 (en) | 2010-02-25 |
| US20050020502A1 (en) | 2005-01-27 |
| US20170281719A1 (en) | 2017-10-05 |
| US20040033243A1 (en) | 2004-02-19 |
| CN100374154C (zh) | 2008-03-12 |
| US20150224166A1 (en) | 2015-08-13 |
| WO2005027954A3 (en) | 2005-10-20 |
| US20210093689A1 (en) | 2021-04-01 |
| WO2005027954A2 (en) | 2005-03-31 |
| JP2006515321A (ja) | 2006-05-25 |
| US6803046B2 (en) | 2004-10-12 |
| US20120128581A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60336509D1 (de) | Zubereitungen enthaltend sincalide | |
| IS6950A (is) | Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma | |
| CY1111872T1 (el) | Συνθεσεις υποτασικου λιπιδιου (προσταγλανδινης) και τιμολολης - σχετικες μεθοδοι χρησης | |
| AU2002360488A8 (en) | Methods and devices for detection and therapy of atheromatous plaque | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| DK1718677T3 (da) | Monovalente antistoffragmenter egnede som terapeutiske midler | |
| MXPA03011006A (es) | Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos. | |
| BR0315157A (pt) | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste | |
| NO20042964L (no) | Spiroazasykliske forbindelser som monoaminreseptormodulatorer | |
| EP1404356A4 (de) | Cd10-aktivierte prodrug-verbindungen | |
| TR200003036T2 (tr) | 12,13-Modifiye edilmiş epotilon türevleri | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE556706T1 (de) | Fettalkohol-arzneimittel-konjugate | |
| WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| AU3831301A (en) | Method for treating ocular pain | |
| AR021778A1 (es) | Composiciones acondicionadoras | |
| NO20043013L (no) | Tetrahydrokinolin analoger som muskarine agonister | |
| PT1052905E (pt) | Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| ATE443044T1 (de) | Tace inhibitoren | |
| DE60213802D1 (de) | Cak inhibitoren und deren verwendungen | |
| ITRM20000266A0 (it) | Procedimento migliorato per la preparazione di (e,z) 3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi. | |
| TW200512009A (en) | Hair treatment compositions | |
| BR0111785A (pt) | Composições e métodos para tratamento de candidìase | |
| EE200200583A (et) | (E)-N-(6,6-dimetüül-2-hepteen-4-ünüül)-N-metüül-1-naftaleenmetaanamiini (terbinafiin) valmistamise meetod |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |